期刊
ARTHRITIS RESEARCH & THERAPY
卷 13, 期 2, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/ar3251
关键词
-
类别
资金
- Rigel pharmaceuticals, San Francisco, CA
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042269] Funding Source: NIH RePORTER
Systemic lupus erythematosus (SLE) is an autoimmune disease resulting from a loss of tolerance to multiple self antigens, and characterized by autoantibody production and inflammatory cell infiltration in target organs, such as the kidneys and brain. T cells are critical players in SLE pathophysiology as they regulate B cell responses and also infiltrate target tissues, leading to tissue damage. Abnormal signaling events link to defective gene transcription and altered cytokine production, contributing to the aberrant phenotype of T cells in SLE. Study of signaling and gene transcription abnormalities in SLE T cells has led to the identification of novel targets for therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据